Vioxx Route To Re-Approval Outlined By FDA As Merck Mulls Options

Conflicting opinions from FDA advisory committee members on the safety of Vioxx necessitates additional committee consideration prior to re-approval of the COX-2 inhibitor, an FDA memo states